Lunai Bioworks Requests Nasdaq Trading Suspension Amid Alleged Short-Selling Abuses
LNAI is trading near its 52-week low of $1.08 (8.8% above the low) on light trading volume (0.1× avg).
Summary
Lunai Bioworks asked Nasdaq to immediately suspend trading in its stock, citing alleged short-selling abuses uncovered in litigation discovery. Nasdaq has not yet responded.
Key Events · Legal and Risk Events · LNAI
-
Trading Suspension Requested
The company formally asked Nasdaq to immediately suspend trading in LNAI common stock to protect investors while authorities review trading records.
-
Alleged Short-Selling Abuses
The submission describes substantial short selling, locate deficiencies, and concentrated failures to deliver based on court-ordered discovery in Lunai Bioworks v. Seven Points Capital LLC et al.
-
No Nasdaq Decision Yet
As of the filing, Nasdaq has not responded. The request itself does not halt trading; any suspension decision remains with Nasdaq.
-
Litigation Continues
The company intends to continue pursuing the pending litigation and related investigation; allegations have not yet been adjudicated.
Analysis · LNAI · Life Sciences
Lunai Bioworks has formally asked Nasdaq to immediately suspend trading in its common stock, citing court-ordered discovery records that allegedly show substantial short selling, locate deficiencies, and concentrated failures to deliver. The request is tied to the company's pending litigation against Seven Points Capital and others. While the request itself does not halt trading, it signals management's belief that the market for its shares may not be fair and orderly — a serious escalation that could lead to a trading halt or suspension if Nasdaq agrees. For a micro-cap company already under going-concern pressure, a suspension would cut off liquidity and could trigger forced selling or margin calls.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1049 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNAI was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $1.08 to $13.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.